The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego. The ADCS is a major initiative for Alzheimer’s disease (AD) clinical studies in the Federal Government, addressing treatments for both cognitive and behavioral symptoms. The ADCS is part of the NIA Division of Neuroscience’s effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and is part of the Alzheimer’s Disease Prevention Initiative as well.
Welcome to the ADCS at UCSD
CURRENT ADCS STUDIES
EXERT is a national, 18-month clinical trial to test whether physical exercise can slow the progression of early Alzheimer’s disease-related memory problems or mild cognitive impairment in older adults. 15 academic medical centers and YMCA’s in the US are participating in the EXERT study.
3 Star Study
Study will research and test whether an investigational vaccine can affect Alzheimer’s disease-related brain changes in participants with Down Syndrome. Criteria to participate is the following: have Down Syndrome, are 35 to 45 years of age, do not have other serious illness, and have a caregiver/informant who can answer questions about them.
ADCS RESEARCH NEWS
What’s next in the Raskind/Peskind Prazosin research? They are directing the ADCS’ Peace AD trial which will test Prazosin, as a treatment for disruptive agitation, in people with moderate to severe Alzheimer’s disease. The trial is launching this spring in over 20 memory and long term care communities in the US.